Skip to main content
main-content

01.03.2018 | Original Article | Ausgabe 7/2018 Open Access

Strahlentherapie und Onkologie 7/2018

Nonmetastatic pancreatic cancer

Improved survival with chemoradiotherapy > 40 Gy after systemic treatment

Zeitschrift:
Strahlentherapie und Onkologie > Ausgabe 7/2018
Autoren:
M.D. Sebastian Bachmayer, M.D. Gerd Fastner, M.D. Andrea Vaszi, M.D. Wolfgang Iglseder, Ph.D. Peter Kopp, M.D. Josef Holzinger, M.D. Adam Dinnewitzer, M.D. Gabriel Rinnerthaler, M.D. Simon Peter Gampenrieder, M.D. Klaus Emmanuel, M.D. Richard Greil, M.D. Felix Sedlmayer, M.D., M.Sc. Franz Zehentmayr
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00066-018-1281-7) contains supplementary material, which is available to authorized users.

Abstract

Purpose

The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy.

Patients and methods

Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50 Gy (range 12–77 Gy), while 61 (84%) patients received >40 Gy.

Results

With a median follow-up of 22 months (range 1.2–179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2‑year survival rate were 22.9 months (1.2–179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with >40 Gy had a survival advantage (median OS 23.7 vs. 17.3 months, p = 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, p = 0.0004).

Conclusion

CRT with total doses >40 Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Radiologie

Kombi-Abonnement

Mit e.Med Radiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Radiologie, den Premium-Inhalten der radiologischen Fachzeitschriften, inklusive einer gedruckten Radiologie-Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary figure 1. Overall survival in resected patients compared by duration of systemic treatment before RT
66_2018_1281_MOESM1_ESM.docx
Supplementary figure 2. Overall survival in unresected patients compared by duration of systemic treatment before RT
66_2018_1281_MOESM2_ESM.docx
Supplementary table 1. Overview of prospective, retrospective and population-based studies
66_2018_1281_MOESM3_ESM.docx
Supplementary table 2. Prospective studies for LAPC
66_2018_1281_MOESM4_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2018

Strahlentherapie und Onkologie 7/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise